EpiAxis Therapeutics Enters Strategic Partnership on Prostate Cancer with Canada’s University Health Newtork (UHN)

EpiAxis Therapeutics is predicated in Sydney, Australia.

EpiAxis Therapeutics and Canada’s University Health Network have entered a collaboration to check a brand new epigenetics strategy to prostate most cancers therapy.

SYDNEY, AUSTRALIA, September 12, 2022 /EINPresswire.com/ — EpiAxis Therapeutics, a number one epigenetics firm with a spotlight on most cancers therapy and prevention recurrence, and University Health Network (UHN) – Canada’s largest and main analysis hospital – have entered right into a collaboration to check a brand new strategy to prostate most cancers therapy.

As a part of the settlement, EpiAxis Therapeutics will provide its lead peptide candidates for evaluation in UHN’s prostate most cancers fashions, with the intention of dramatically enhancing the flexibility to enhance therapy and survival of males with deadly prostate most cancers (CaP).

EpiAxis Therapeutics CEO, Dr Jeremy Chrisp, stated that whereas subsequent era genomic applied sciences have deepened the understanding of prostate most cancers improvement and evolution, they’ve arguably reached a therapeutic plateau.

“Most FDA-approved indications are for established targets in earlier disease states, rather than novel targets,” Dr Chrisp stated. “Our first-in-class assets have dual action, and target dormant chemotherapy-resistant cells while also improving the immune response against the persisting cells. EpiAxis is very pleased to be supplying our lead peptides candidates to UHN in hope of accelerating innovation in the treatment of CaP.”

Dr Hansen He, Senior Scientist at UHN’s Princess Margaret Cancer Centre, can be main the undertaking utilising EpiAxis’ lead peptide candidates.

Dr He’s analysis program focuses on understanding epigenetic mechanisms underlying most cancers improvement, development and remedy response, with the intention of figuring out epigenetic biomarkers and therapeutic targets to enhance therapy outcomes for most cancers sufferers.

“We are excited to collaborate with EpiAxis to target the epigenetic regulator LSD1 in advanced prostate cancer. This leverages our deep understanding of the epigenetic mechanisms and the potent effect of LSD1 peptide inhibitors developed by EpiAxis,” Dr He stated.

EpiAxis is suggested by The Sage Group (New York and London).

For extra details about the partnership between EpiAxis Therapeutics and UHN, please contact:

Dr Jeremy Chrisp

Phone: +61 421 012 268

[email protected]

ABOUT EPIAXIS THERAPEUTICS

EpiAxis is a number one drug improvement firm primarily based in Sydney, Australia, that goals to make most cancers a continual illness relatively than a deadly one, through the use of epigenetic science to create a totally completely different strategy to most cancers therapy. Our therapies work in a different way to current – and infrequently poisonous – therapies by reprogramming the most cancers cells again in the direction of regular cells. For extra details about EpiAxis go to www.epiaxistherapeutics.com

ABOUT UHN

University Health Network consists of Toronto General and Toronto Western hospitals, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, and The Michener Institute of Education at UHN. The scope of analysis and complexity of circumstances at University Health Network has made it a nationwide and worldwide supply for discovery, schooling and affected person care. It has the most important hospital-based analysis program in Canada, with main analysis in arthritis, cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious illnesses, genomic drugs and rehabilitation drugs. University Health Network is a analysis hospital affiliated with the University of Toronto.

Dr. Jeremy Chrisp
EpiAxis Therapeutics
+61 421 012 268
electronic mail us right here